Caribou Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview - TradingView

Caribou Biosciences Inc CRBU is expected to show a rise in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025 The Berkeley California-based company is expected to report a 30.9% increase in revenue to $2.65 million from $2.02 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data. ​LSEG's mean analyst estimate for Caribou Biosciences Inc is for a loss of 36 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Caribou Biosciences Inc is $5.00, about 53.6% above its last closing price of $2.32